Skip to main content
Top
Published in: World Journal of Surgical Oncology 1/2012

Open Access 01-12-2012 | Research

Different distribution of breast ductal carcinoma in situ, ductal carcinoma in situ with microinvasion, and invasion breast cancer

Authors: Zhang Wei, Gao Er-li, Zhou Yi-li, Zhai Qi, Zou Zhang-yong, Guo Gui-long, Chen Guo-rong, Zheng Hua-min, Huang Guan-li, Zhang Xiao-hua

Published in: World Journal of Surgical Oncology | Issue 1/2012

Login to get access

Abstract

Background

Breast ductal cancer in situ (DCIS) can recur or progress to invasive ductal cancer (IDC), and the interim stage include DCIS with microinvasion (DCIS-Mi). In this article, we attempt to study the study the differences of clinicopathological features, imaging data, and immunohistochemical-based subtypes among DCIS, DCIS-Mi, and IDC.

Methods

In this retrospective study, we attempt to compare the clinicopathological features, immunohistochemical results and imaging data of 866 patients (included 73 DCIS, 72 DCIS-Mi, and 721 IDC).

Results

Patients with DCIS and DCIS-Mi were younger than those with IDC (P = 0.007). DCIS and DCIS-Mi often happened in premenopausal women while IDC was opposite (P <0.001). The incidence of IDC with node-positive was significantly higher than it in DCIS and DCIS-Mi (P <0.001). We also observed that the Her2-positive was more often found in patients with pure DCIS compared to those with DCIS-Mi and DCIS-I (P <0.001). There was a significant difference between the four subgroups (Luminal-A, Luminal-B, ERBB2+, Basal-like) from DCIS, DCIS-Mi, and IDC (P <0.001). Basal-like patients were fewer than other subgroups in DCIS, DCIS-Mi, and IDC. The incidence of the first performance of ultrasound (catheter winded and nodular mass) and mammography (nodular mass) had significantly difference among patients with DCIS, DCIS-Mi, and IDC (P <0.001).

Conclusions

Different clinicopathological, immunohistochemical, and imaging features among DCIS, DCIS-Mi, and IDC indicate that they are distinct entities. A larger sample size is needed for further study.
Literature
1.
go back to reference DeSantis C, Siegel R, Bandi P, Jemal A: Breast cancer statistics. CA Cancer J Clin. 2011, 61: 409-418.CrossRefPubMed DeSantis C, Siegel R, Bandi P, Jemal A: Breast cancer statistics. CA Cancer J Clin. 2011, 61: 409-418.CrossRefPubMed
2.
go back to reference Wiechmann L, Kuerer HM: The molecular journey from ductal carcinoma in situ to invasive breast cancer. Cancer. 2008, 112: 2130-2142. 10.1002/cncr.23430.CrossRefPubMed Wiechmann L, Kuerer HM: The molecular journey from ductal carcinoma in situ to invasive breast cancer. Cancer. 2008, 112: 2130-2142. 10.1002/cncr.23430.CrossRefPubMed
3.
go back to reference Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL: Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002, 20: 3628-3636. 10.1200/JCO.2002.02.026.CrossRefPubMed Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL: Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002, 20: 3628-3636. 10.1200/JCO.2002.02.026.CrossRefPubMed
4.
go back to reference Bianchi S, Vezzosi V: Microinvasive carcinoma of the breast. Pathol Oncol Res. 2008, 14: 105-111. 10.1007/s12253-008-9054-8.CrossRefPubMed Bianchi S, Vezzosi V: Microinvasive carcinoma of the breast. Pathol Oncol Res. 2008, 14: 105-111. 10.1007/s12253-008-9054-8.CrossRefPubMed
5.
go back to reference Schuh ME, Nemoto T, Penetrante RB, Rosner D, Dao TL: Intraductal carcinoma. Analysis of presentation, pathologic findings, and outcome of disease. Arch Surg. 1986, 121: 1303-1307. 10.1001/archsurg.1986.01400110095016.CrossRefPubMed Schuh ME, Nemoto T, Penetrante RB, Rosner D, Dao TL: Intraductal carcinoma. Analysis of presentation, pathologic findings, and outcome of disease. Arch Surg. 1986, 121: 1303-1307. 10.1001/archsurg.1986.01400110095016.CrossRefPubMed
6.
go back to reference Wong JH, Kopald KH, Morton DL: The impact of microinvasion on axillary node metastases and survival in patients with intraductal breast cancer. Arch Surg. 1990, 125: 1298-1301. 10.1001/archsurg.1990.01410220082011.CrossRefPubMed Wong JH, Kopald KH, Morton DL: The impact of microinvasion on axillary node metastases and survival in patients with intraductal breast cancer. Arch Surg. 1990, 125: 1298-1301. 10.1001/archsurg.1990.01410220082011.CrossRefPubMed
7.
go back to reference Strnad P: The 5th edition of the TNM classification–malignant tumors of the breast. Ceska Gynekol. 1999, 64: 54-57.PubMed Strnad P: The 5th edition of the TNM classification–malignant tumors of the breast. Ceska Gynekol. 1999, 64: 54-57.PubMed
8.
go back to reference Perry N, Broeders M, de Wolf C, Tornberg S, Holland R, von Karsa L: European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition–summary document. Ann Oncol. 2008, 19: 614-622.CrossRefPubMed Perry N, Broeders M, de Wolf C, Tornberg S, Holland R, von Karsa L: European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition–summary document. Ann Oncol. 2008, 19: 614-622.CrossRefPubMed
9.
go back to reference de Mascarel I, MacGrogan G, Mathoulin-Pelissier S, Soubeyran I, Picot V, Coindre JM: Breast ductal carcinoma in situ with microinvasion: a definition supported by a long-term study of 1248 serially sectioned ductal carcinomas. Cancer. 2002, 94: 2134-2142. 10.1002/cncr.10451.CrossRefPubMed de Mascarel I, MacGrogan G, Mathoulin-Pelissier S, Soubeyran I, Picot V, Coindre JM: Breast ductal carcinoma in situ with microinvasion: a definition supported by a long-term study of 1248 serially sectioned ductal carcinomas. Cancer. 2002, 94: 2134-2142. 10.1002/cncr.10451.CrossRefPubMed
10.
go back to reference Yu KD, Wu LM, Liu GY, Wu J, Di GH, Shen ZZ, Shao ZM: Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component. Ann Surg Oncol. 2011, 18: 1342-1348. 10.1245/s10434-010-1407-3.CrossRefPubMed Yu KD, Wu LM, Liu GY, Wu J, Di GH, Shen ZZ, Shao ZM: Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component. Ann Surg Oncol. 2011, 18: 1342-1348. 10.1245/s10434-010-1407-3.CrossRefPubMed
11.
go back to reference Okumura Y, Yamamoto Y, Zhang Z, Toyama T, Kawasoe T, Ibusuki M, Honda Y, Iyama K, Yamashita H, Iwase H: Identification of biomarkers in ductal carcinoma in situ of the breast with microinvasion. BMC Cancer. 2008, 8: 287-10.1186/1471-2407-8-287.PubMedCentralCrossRefPubMed Okumura Y, Yamamoto Y, Zhang Z, Toyama T, Kawasoe T, Ibusuki M, Honda Y, Iyama K, Yamashita H, Iwase H: Identification of biomarkers in ductal carcinoma in situ of the breast with microinvasion. BMC Cancer. 2008, 8: 287-10.1186/1471-2407-8-287.PubMedCentralCrossRefPubMed
12.
go back to reference Vieira CC, Mercado CL, Cangiarella JF, Moy L, Toth HK, Guth AA: Microinvasive ductal carcinoma in situ: clinical presentation, imaging features, pathologic findings, and outcome. Eur J Radiol. 2010, 73: 102-107. 10.1016/j.ejrad.2008.09.037.CrossRefPubMed Vieira CC, Mercado CL, Cangiarella JF, Moy L, Toth HK, Guth AA: Microinvasive ductal carcinoma in situ: clinical presentation, imaging features, pathologic findings, and outcome. Eur J Radiol. 2010, 73: 102-107. 10.1016/j.ejrad.2008.09.037.CrossRefPubMed
13.
go back to reference Dupont WD, Parl FF, Hartmann WH, Brinton LA, Winfield AC, Worrell JA, Schuyler PA, Plummer WD: Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer. 1993, 71: 1258-1265. 10.1002/1097-0142(19930215)71:4<1258::AID-CNCR2820710415>3.0.CO;2-I.CrossRefPubMed Dupont WD, Parl FF, Hartmann WH, Brinton LA, Winfield AC, Worrell JA, Schuyler PA, Plummer WD: Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer. 1993, 71: 1258-1265. 10.1002/1097-0142(19930215)71:4<1258::AID-CNCR2820710415>3.0.CO;2-I.CrossRefPubMed
14.
go back to reference Carter CL, Corle DK, Micozzi MS, Schatzkin A, Taylor PR: A prospective study of the development of breast cancer in 16,692 women with benign breast disease. Am J Epidemiol. 1988, 128: 467-477.PubMed Carter CL, Corle DK, Micozzi MS, Schatzkin A, Taylor PR: A prospective study of the development of breast cancer in 16,692 women with benign breast disease. Am J Epidemiol. 1988, 128: 467-477.PubMed
15.
go back to reference Nagle RB, Bocker W, Davis JR, Heid HW, Kaufmann M, Lucas DO, Jarasch ED: Characterization of breast carcinomas by two monoclonal antibodies distinguishing myoepithelial from luminal epithelial cells. J Histochem Cytochem. 1986, 34: 869-881. 10.1177/34.7.2423579.CrossRefPubMed Nagle RB, Bocker W, Davis JR, Heid HW, Kaufmann M, Lucas DO, Jarasch ED: Characterization of breast carcinomas by two monoclonal antibodies distinguishing myoepithelial from luminal epithelial cells. J Histochem Cytochem. 1986, 34: 869-881. 10.1177/34.7.2423579.CrossRefPubMed
16.
go back to reference Pinder SE: Ductal carcinoma in situ (DCIS): pathological features, differential diagnosis, prognostic factors and specimen evaluation. Mod Pathol. 2010, Suppl 2: S8-13.CrossRef Pinder SE: Ductal carcinoma in situ (DCIS): pathological features, differential diagnosis, prognostic factors and specimen evaluation. Mod Pathol. 2010, Suppl 2: S8-13.CrossRef
17.
go back to reference Yu KD, Di GH, Wu J, Lu JS, Shen KW, Shen ZZ, Shao ZM: Development and trends of surgical modalities for breast cancer in China: a review of 16-year data. Ann Surg Oncol. 2007, 14: 2502-2509. 10.1245/s10434-007-9436-2.CrossRefPubMed Yu KD, Di GH, Wu J, Lu JS, Shen KW, Shen ZZ, Shao ZM: Development and trends of surgical modalities for breast cancer in China: a review of 16-year data. Ann Surg Oncol. 2007, 14: 2502-2509. 10.1245/s10434-007-9436-2.CrossRefPubMed
18.
go back to reference Fan L, Zheng Y, Yu KD, Liu GY, Wu J, Lu JS, Shen KW, Shen ZZ, Shao ZM: Breast cancer in a transitional society over 18 years: trends and present status in Shanghai. China. Breast Cancer Res Treat. 2009, 117: 409-416. 10.1007/s10549-008-0303-z.CrossRefPubMed Fan L, Zheng Y, Yu KD, Liu GY, Wu J, Lu JS, Shen KW, Shen ZZ, Shao ZM: Breast cancer in a transitional society over 18 years: trends and present status in Shanghai. China. Breast Cancer Res Treat. 2009, 117: 409-416. 10.1007/s10549-008-0303-z.CrossRefPubMed
19.
go back to reference Fu LN, Wang Y, Huang YH: Value of ultrasound elastography in detecting small breast tumors. Chin Med J (Engl). 2011, 124: 2384-2386. Fu LN, Wang Y, Huang YH: Value of ultrasound elastography in detecting small breast tumors. Chin Med J (Engl). 2011, 124: 2384-2386.
20.
go back to reference Lawson JS, Field AS, Tran DD, Killeen J, Maskarenic G, Ishikura H, Trichopoulos D: Breast cancer incidence and estrogen receptor alpha in normal mammary tissue–an epidemiologic study among Japanese women in Japan and Hawaii. Int J Cancer. 2002, 97: 685-687. 10.1002/ijc.10093.CrossRefPubMed Lawson JS, Field AS, Tran DD, Killeen J, Maskarenic G, Ishikura H, Trichopoulos D: Breast cancer incidence and estrogen receptor alpha in normal mammary tissue–an epidemiologic study among Japanese women in Japan and Hawaii. Int J Cancer. 2002, 97: 685-687. 10.1002/ijc.10093.CrossRefPubMed
21.
go back to reference Collins LC, Schnitt SJ: HER2 protein overexpression in estrogen receptor-positive ductal carcinoma in situ of the breast: frequency and implications for tamoxifen therapy. Mod Pathol. 2005, 18: 615-620. 10.1038/modpathol.3800360.CrossRefPubMed Collins LC, Schnitt SJ: HER2 protein overexpression in estrogen receptor-positive ductal carcinoma in situ of the breast: frequency and implications for tamoxifen therapy. Mod Pathol. 2005, 18: 615-620. 10.1038/modpathol.3800360.CrossRefPubMed
22.
go back to reference Daly MB: Tamoxifen in ductal carcinoma in situ. Semin Oncol. 2006, 33: 647-649. 10.1053/j.seminoncol.2006.08.019.CrossRefPubMed Daly MB: Tamoxifen in ductal carcinoma in situ. Semin Oncol. 2006, 33: 647-649. 10.1053/j.seminoncol.2006.08.019.CrossRefPubMed
23.
go back to reference Ooi A, Takehana T, Li X, Suzuki S, Kunitomo K, Iino H, Fujii H, Takeda Y, Dobashi Y: Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod Pathol. 2004, 17: 895-904. 10.1038/modpathol.3800137.CrossRefPubMed Ooi A, Takehana T, Li X, Suzuki S, Kunitomo K, Iino H, Fujii H, Takeda Y, Dobashi Y: Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod Pathol. 2004, 17: 895-904. 10.1038/modpathol.3800137.CrossRefPubMed
24.
go back to reference Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM: Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res. 2004, 10: 7621-7628. 10.1158/1078-0432.CCR-04-1061.CrossRefPubMed Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM: Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res. 2004, 10: 7621-7628. 10.1158/1078-0432.CCR-04-1061.CrossRefPubMed
25.
go back to reference Schimmelpenning H, Eriksson ET, Falkmer UG, Azavedo E, Svane G, Auer GU: Expression of the c-erbB-2 proto-oncogene product and nuclear DNA content in benign and malignant human breast parenchyma. Virchows Arch A Pathol Anat Histopathol. 1992, 420: 433-440. 10.1007/BF01600515.CrossRefPubMed Schimmelpenning H, Eriksson ET, Falkmer UG, Azavedo E, Svane G, Auer GU: Expression of the c-erbB-2 proto-oncogene product and nuclear DNA content in benign and malignant human breast parenchyma. Virchows Arch A Pathol Anat Histopathol. 1992, 420: 433-440. 10.1007/BF01600515.CrossRefPubMed
26.
go back to reference Pavelic ZP, Pavelic L, Lower EE, Gapany M, Gapany S, Barker EA: Preisler HD: c-myc, c-erbB-2, and Ki-67 expression in normal breast tissue and in invasive and noninvasive breast carcinoma. Cancer Res. 1992, 52: 2597-2602.PubMed Pavelic ZP, Pavelic L, Lower EE, Gapany M, Gapany S, Barker EA: Preisler HD: c-myc, c-erbB-2, and Ki-67 expression in normal breast tissue and in invasive and noninvasive breast carcinoma. Cancer Res. 1992, 52: 2597-2602.PubMed
27.
go back to reference Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, Osborne CK, Tormey DC, McGuire WL: Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol. 1992, 23: 974-979. 10.1016/0046-8177(92)90257-4.CrossRefPubMed Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, Osborne CK, Tormey DC, McGuire WL: Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol. 1992, 23: 974-979. 10.1016/0046-8177(92)90257-4.CrossRefPubMed
28.
go back to reference Hoque A, Sneige N, Sahin AA, Menter DG, Bacus JW, Hortobagyi GN, Lippman SM: Her-2/neu gene amplification in ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev. 2002, 11: 587-590.PubMed Hoque A, Sneige N, Sahin AA, Menter DG, Bacus JW, Hortobagyi GN, Lippman SM: Her-2/neu gene amplification in ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev. 2002, 11: 587-590.PubMed
29.
go back to reference Mylonas I, Makovitzky J, Jeschke U, Briese V, Friese K, Gerber B: Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma in situ (DCIS) versus invasive breast cancer alone. Anticancer Res. 2005, 25: 1719-1723.PubMed Mylonas I, Makovitzky J, Jeschke U, Briese V, Friese K, Gerber B: Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma in situ (DCIS) versus invasive breast cancer alone. Anticancer Res. 2005, 25: 1719-1723.PubMed
30.
go back to reference Dupont WD, Page DL: Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985, 312: 146-151. 10.1056/NEJM198501173120303.CrossRefPubMed Dupont WD, Page DL: Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985, 312: 146-151. 10.1056/NEJM198501173120303.CrossRefPubMed
31.
go back to reference London SJ, Connolly JL, Schnitt SJ, Colditz GA: A prospective study of benign breast disease and the risk of breast cancer. JAMA. 1992, 267: 941-944. 10.1001/jama.1992.03480070057030.CrossRefPubMed London SJ, Connolly JL, Schnitt SJ, Colditz GA: A prospective study of benign breast disease and the risk of breast cancer. JAMA. 1992, 267: 941-944. 10.1001/jama.1992.03480070057030.CrossRefPubMed
32.
go back to reference Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, Vierkant RA, Maloney SD, Pankratz VS, Hillman DW, Suman VJ, Johnson J, Blake C, Tlsty T, Vachon CM, Melton LJ, Visccher DW: Benign breast disease and the risk of breast cancer. N Engl J Med. 2005, 353: 229-237. 10.1056/NEJMoa044383.CrossRefPubMed Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, Vierkant RA, Maloney SD, Pankratz VS, Hillman DW, Suman VJ, Johnson J, Blake C, Tlsty T, Vachon CM, Melton LJ, Visccher DW: Benign breast disease and the risk of breast cancer. N Engl J Med. 2005, 353: 229-237. 10.1056/NEJMoa044383.CrossRefPubMed
33.
go back to reference Worsham MJ, Raju U, Lu M, Kapke A, Botttrell A, Cheng J, Shah V, Savera A, Wolman SR: Risk factors for breast cancer from benign breast disease in a diverse population. Breast Cancer Res Treat. 2009, 118: 1-7. 10.1007/s10549-008-0198-8.PubMedCentralCrossRefPubMed Worsham MJ, Raju U, Lu M, Kapke A, Botttrell A, Cheng J, Shah V, Savera A, Wolman SR: Risk factors for breast cancer from benign breast disease in a diverse population. Breast Cancer Res Treat. 2009, 118: 1-7. 10.1007/s10549-008-0198-8.PubMedCentralCrossRefPubMed
34.
go back to reference Kabat GC, Jones JG, Olson N, Negassa A, Duggan C, Ginsberg M, Kandel RA, Glass AG, Rohan TE: A multi-center prospective cohort study of benign breast disease and risk of subsequent breast cancer. Cancer Causes Control. 2010, 21: 821-828. 10.1007/s10552-010-9508-7.PubMedCentralCrossRefPubMed Kabat GC, Jones JG, Olson N, Negassa A, Duggan C, Ginsberg M, Kandel RA, Glass AG, Rohan TE: A multi-center prospective cohort study of benign breast disease and risk of subsequent breast cancer. Cancer Causes Control. 2010, 21: 821-828. 10.1007/s10552-010-9508-7.PubMedCentralCrossRefPubMed
Metadata
Title
Different distribution of breast ductal carcinoma in situ, ductal carcinoma in situ with microinvasion, and invasion breast cancer
Authors
Zhang Wei
Gao Er-li
Zhou Yi-li
Zhai Qi
Zou Zhang-yong
Guo Gui-long
Chen Guo-rong
Zheng Hua-min
Huang Guan-li
Zhang Xiao-hua
Publication date
01-12-2012
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2012
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-10-262

Other articles of this Issue 1/2012

World Journal of Surgical Oncology 1/2012 Go to the issue